LIPOSORBER® Provides Hope When Drug Therapy Fails™
For Your Familial Hypercholesterolemia (FH) Patients
Consider LIPOSORBER for your FH patients levels when drug therapies (statins, PCSK9is) fail to achieve the recommended therapeutic targets per established clinical guidelines. The system effectively removes harmful atherogenic lipoproteins associated with serious cardiovascular disease and vascular complications in FH patients.
For Your Focal Segmental Glomerulosclerosis (FSGS) Patients
Consider LIPOSORBER for your adult and pediatric primary FSGS patients when therapies have failed or are not well-tolerated or if FSGS recurs post renal transplantation. LIPOSORBER enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.1*
Offer a comprehensive
line to your practice
Find a Center
Locate a center
closest to you
Review videos, physician
education materials &
- Muso, E et al. “Immediate therapeutic efficacy of LDL apheresis for drug-resistant nephrotic Syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8
*Based on a study that took place over two (2) years.